Altered Estrogen Receptor Signaling Pathway in BRCA2-Deficient Estrogen Receptor-Positive/HER2-Negative Breast Cancer.
BRCA2-linked breast cancers may benefit from adding a PARP inhibitor to hormone therapy, combining two treatment strategies for hereditary cases.
This Osaka University study provides the first detailed characterization of estrogen receptor signaling alterations in BRCA2 germline variant ER+/HER2- breast cancers using matched IHC in patient tumors (n=8 vs n=59 controls) and CRISPR-Cas9-generated BRCA2-deficient cell lines. The finding that BRCA2 loss increases olaparib sensitivity without altering tamoxifen sensitivity suggests a precision medicine rationale for incorporating PARP inhibitor therapy in this ER+ hereditary subgroup.
What the study was
- Study design
- Case-control IHC analysis + CRISPR-Cas9 in vitro mechanistic study
- Population
- BRCA2 PV carriers with ER+/HER2- breast cancer (n=8 carriers) vs BRCA2 wild-type (n=59); MCF7-derived BRCA2-KO cell lines
- Sample size
- 67
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Cancer Reports (Hoboken)
Why it surfaced
First characterization of ER signaling in BRCA2-deficient ER+ breast cancer provides biological rationale for PARP inhibitor use in this ER+ hereditary subgroup; small n=8 BRCA2 carrier cohort limits statistical power but CRISPR validation strengthens mechanistic conclusions.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.